Exhibit 10.24**FOURTH AMENDMENT of the LICENSE AGREEMENT**This Fourth Amendment of the License Agreement is made this 28th day of September2005 (the “Fourth Amendment”) by and between **IDM Pharma, Inc.**(formerly Epimmune Inc. (hereinafterreferred to as “Epimmune”)), having an office and a place of business at **5820**Nancy Ridge Drive,San Diego, California 92121 U.S.A (hereinafter referred to as “IDMI”), and **Innogenetics N.V.**,having an office and a place of business at Technologiepark 6, B-9052 Ghent, Belgium (hereinafterreferred to as “INNX”), to amend the License Agreement dated July 9, 2001 between IDMI and INNX(the “Agreement”) as amended by a First Amendment of the License Agreement, dated October 16, 2002(the “First Amendment”), a Second Amendment of the License Agreement, dated March 15, 2004 (the“Second Amendment”) and a Third Amendment of the License Agreement, dated March 29, 2004 (the“Third Amendment”).WHEREAS :**•** Epimmune and Genencor International, Inc. (“GCOR”) executed the Agreement; **•** Epimmune and GCOR executed the First Amendment and the Second Amendment; **•** GCOR assigned this Agreement, amended as aforesaid, to INNX by virtue of an Assignment and, in that capacity, INNXreplaced GCOR as a signatory to the Agreement; **•** Epimmune and INNX executed the Third Amendment; **•** Epimmune Inc. combined with IDM S.A. and changed its name to IDM Pharma, Inc.; and **•** IDMI and INNX (hereinafter sometimes individually referred to as the “Party” and collectively as the “Parties”) aredesirous of extending the Agreement in scope and duration as specified herein under the following terms and conditions.NOW THEREFORE, the Parties hereto agree to amend the Agreement, as follows:1. The Parties acknowledge that, as of the Effective Date of this Fourth Amendment, referencesto EPMN in the Agreement, as amended by the First Amendment, the Second Amendment, the ThirdAmendment and this Fourth Amendment, shall be amended so as to replace “EPMN” with “IDMI.” 2. Section 1.6 shall be amended to read, as follows:   “1.6 “Collaboration Term” shall mean the five (5) year period from April 2, 2001through March 30, 2006, unless extended by mutual agreement or terminated early asprovided for in the Collaboration Agreement.”The Parties hereto further agree, as follows:**1.** **Other Terms Remain in Effect.**All terms and conditions of the License Agreement, as amendedby the First Amendment and the Second Amendment and the Third Amendment, which are notmodified by this Fourth Amendment, shall remain in full force and effect. From and after theEffective Date of this Fourth Amendment, for purposes of the License Agreement, the term“Agreement” shall be deemed to mean the License Agreement, the First Amendment, the SecondAmendment, the Third Amendment and this Fourth Amendment. **2.** **Miscellaneous.**This Fourth Amendment shall be governed by and construed under the laws ofthe State of California as applied to agreements among California residents entered into andto be performed entirely within California. The provisions hereof shall inure to the benefitof, and be binding upon, the successors and assigns of Innogenetics and the Company. **3.** **Effective Date**. This Fourth Amendment shall be effective upon that date on which the last ofthe signatures set forth below has been affixed hereto.
1

 
IN WITNESS WHEREOF, the Parties hereto have executed this Amendment in two (2) original copies bythemselves or their duly authorized representatives, as follows:     For **Innogenetics N.V.**:   For **IDM Pharma, Inc.**:     /s/ Frank Morich   /s/ Robert De Vaere     Frank Morich